We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Expands FDG-PET Coverage for Multiple Forms of Cancer
CMS Expands FDG-PET Coverage for Multiple Forms of Cancer
February 11, 2005
The Centers for Medicare & Medicaid Services (CMS) issued a final decision memorandum that will lead to reimbursement for a broad range of oncology studies in which positron emission tomography (PET) with fluoro-2-deoxy-D glucose (FDG) is used, increasing cancer patients’ access to this therapeutic agent and improving the diagnosis and treatment of cancer patients nationwide.